Evidence map›Paper›PMID 30140328›Full record

Trial reportPain research & management2018

An Assessment of Clinically Important Differences on the Worst Pain Severity Item of the Modified Brief Pain Inventory in Patients with Diabetic Peripheral Neuropathic Pain.

James Marcus, Kathryn Lasch, Yin Wan, Mei Yang, Ching Hsu, Domenico Merante

2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Pain research & management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04924010 nacompletednot on this mapstarted 2021, after this paper: background citation

Effect of Perioperative Cognitive Behavioural Therapy on Chronic Persistent Postsurgical Pain Among Breast Cancer Patients With High Pain Catastrophising Characteristics: A Randomised, Double-blind Clinical Trial

TypeinterventionalSponsorMater Misericordiae University HospitalRan2021 to 2023Enrolled48ConditionsBreast Cancer, Chronic Pain, Chronic Postsurgical Pain, Quality of LifeArmsCognitive Behavioural Therapy (CBT), Education and Mindfulness
NCT06834685 narecruitingnot on this mapstarted 2025, after this paper: background citation

Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy: a Randomized, Non-comparative, Placebo-controlled, Single-blinded, Phase II Clinical Trial in Cancer Patients

TypeinterventionalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2025 to 2028Enrolled70ConditionsCancer Survivors, Peripheral Neuropathic PainArmsPhotobiomodulation sessions
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

James MarcusPharmerit International, Bethesda, MD, USA.ORCID 0000-0001-5223-4173
Kathryn LaschPharmerit International, Boston, MA, USA.ORCID 0000-0002-5332-2906
Yin WanPharmerit International, Bethesda, MD, USA.
Mei YangDaiichi Sankyo, Inc., Basking Ridge, NJ, USA.
Ching HsuDaiichi Sankyo, Inc., Basking Ridge, NJ, USA.
Domenico MeranteDaiichi Sankyo Development Ltd., Gerrards Cross, Buckinghamshire, UK.
Pharmerit (United States) · USDaiichi Sankyo (United States) · USDaiichi Sankyo (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Using patient global impression of change (PGIC) as an anchor, an approximately 30% reduction on an 11-point numeric pain intensity rating scale (PI-NRS) is considered a clinically important difference (CID) in pain. Our objective was to define the CID for another pain measure, the worst pain severity (WPS) item of the modified Brief Pain Inventory (m-BPI). Methods: In this post hoc analysis of a double-blind, placebo-controlled, phase 2 study, 452 randomized patients with diabetic peripheral neuropathic pain (DPNP) were followed over 5 weeks, with m-BPI data collected weekly and PGIC at treatment conclusion. Receiver operating characteristic (ROC) curves (via logistic regression) were used to determine the changes in the m-BPI-WPS score that best predicted ordinal clinical improvement thresholds (i.e., "minimally improved" or better) on the PGIC. Results: Similar to the PI-NRS, a change of -3 (raw) or -33.3% from the baseline on the m-BPI-WPS optimized prediction for the "much improved" or better PGIC threshold and represents a CID. There was a high correspondence between observed and predicted PGIC categories at each PGIC threshold (ROC AUCs were 0.78-0.82). Conclusions: Worst pain on the m-BPI may be used to assess clinically important improvements in DPNP studies. Findings require validation in larger studies.

Indexed as

Outcome Assessment, Health CarePainBridged Bicyclo CompoundsDiabetic NeuropathiesDouble-Blind MethodFemaleHumansHypoglycemic AgentsMalePain MeasurementROC CurveStatistics as TopicBridged Bicyclo CompoundsHypoglycemic Agentsmirogabalin

Identifiers

PMID30140328
PMCPMC6081576
OpenAlexW2884682969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.